Crisis in Vaginal Health Care
Millions of women. The #1 reason for medical visits. $20B in annual healthcare costs. Vaginal health deserves better.1
Recurrent and chronic conditions originate from imbalances in the vaginal microbiome
Doctors only give me antibiotics, but the problem keeps coming back...
Annabelle, 41 y.o
I’ve tried everything, but nothing works long-term.
Alyssa, 46 y.o
I feel embarrassed to talk about it, but I need real answers.
Chloe, 35 y.o
Imbalances in the vaginal microbiome are often overlooked, resulting in chronic and misdiagnosed infections, leaving women with ineffective and inadequate treatment.
Vaginal dysbiosis, including Bacterial Vaginosis, affect 30% of women aged 14-49, and up to 50% of Black women 2,3; 45% of women suffer from chronic yeast infections; 42 million women suffer from chronic UTIs; 27 million women suffer from vulvar conditions; over 10 million post cancer survivors suffer from multiple vaginal conditions; 63 million women in per- and post-menopause suffer from vaginal atrophy and related conditions.
Without restoring the microbiome, standard treatments provide only temporary relief, leaving many women stuck in a cycle of recurring infections.With actionable microbiome insights and clinician oversight, Good Clean Clinical Care™ helps personalize treatment decisions while supporting comfort, tolerability, and long-term vaginal wellness.
Shop Treatments
Find science-backed solutions for your condition
BiomeNourish™ Difference
The first and only prescription base formulated for the vaginal and vulvar microbiome.
Our Approach
Microbiome-first science in prescription care to transform your vaginal health
Our Research
Our pioneering study advancing personalized care through vaginal microbiome research.
References:
- Multiple Sources Cited: Center for Disease Control, NIH, John Hopkins Medicine, US Dept of Labor, Reed et al. 2015, Medina et al 2019, Chu et al. 2018, Health System Tracker.
- ARPA-H Vulvar Health Document, & Vulvar and Vaginal Microbiome in Health and Disease (2023).
- Watkins, et al. (2023), & treatment Patterns and Economic Burden of Bacterial Vaginosis Among Commercially Insured Women. Analysis of the high recurrence rates of BV and its economic burden on healthcare systems.
- High Global Burden and Costs of Bacterial Vaginosis (2023). An in-depth look at the global impact and financial burden of bacterial vaginosis on women’s health.